Exosome-dopamine conjugated compound, gel patch containing compound as well as preparation method and application of gel patch

Through the combination of exosome-dopamine conjugated complex and bioactive biomimicking hydrogel, the prepared gel patch achieves axonal regeneration and motor function recovery of diabetic peripheral neuropathy, solving the difficulty of reversal of treatment in the prior art Problems with peripheral neuropathy and motor function recovery significantly improve neuroprotection and functional recovery effects.

CN118903204APending Publication Date: 2024-11-08SICHUAN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410947400.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The treatment of diabetic peripheral neuropathy faces the problems of complex pathogenesis, diverse symptoms, limited therapeutic drugs, difficult to reverse disease progression and difficulty in self-management of patients. The existing technology is difficult to effectively promote axon regeneration and motor function recovery.

Method used

The combination of exosome-dopamine conjugated complex and bioactive biomimicry hydrogel is used to prepare gel patches through cross-linking of dynamic imine bonds and boron ester bonds to achieve mitochondrial targeting regulation and microenvironment remodeling, and promote axis Regeneration and neuroprotection.

Benefits of technology

Effectively promote axonal regeneration, myelination and motor function recovery in rats with diabetic peripheral neuropathy, significantly reduce cell apoptosis and oxidative stress, and improve neurological function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903204A_ABST
    Figure CN118903204A_ABST
Patent Text Reader

Abstract

The invention provides an exosome-dopamine conjugated compound, which is prepared by using dopamine methacrylate and an exosome as raw materials, and the molar ratio of the dopamine methacrylate to the exosome is 1: (1-5). The invention also provides a preparation method of the exosome-dopamine conjugated compound, and a gel patch containing the compound. The invention also provides application of the gel patch in preparation of an external medicine or a subcutaneous implantation medicament with a nerve protection effect. The exosome derived from the bone marrow mesenchymal stem cells and the dopamine methacrylate are combined for use, a synergistic effect is exerted in a conjugated compound form, and the prepared gel patch can effectively promote diabetic axon regeneration, myelin sheath formation and motor function recovery.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an exosome-dopamine conjugate complex, a gel patch containing the complex, and a preparation method and application thereof. Background Art

[0002] Diabetic peripheral nerve injury (DPI) Diabetic peripheral neuropathy (DPN) is one of the common complications of diabetic patients. Strict control of blood sugar levels is the primary and basic treatment measure for DPI. Good blood sugar control can slow the progression of DPN. In terms of drug treatment, it includes neurotrophic drugs: such as methylcobalamin, which can promote nerve repair and improve nerve conduction velocity; antioxidant stress drugs: such as α-lipoic acid, which protects nerve cells by scavenging free radicals; aldose reductase inhibitors: such as epalrestat, which reduce abnormal activation of polyol pathways and improve metabolic disorders; microcirculation-improving drugs: such as pentoxifylline and pancreatic kallikrein, which relieve symptoms by improving blood circulation; analgesics: for painful DPI, anticonvulsants (such as pregabalin, gabapentin), antidepressants (such as duloxetine, amitriptyline), opioids (such as tramadol), etc. are used.

[0003] The treatment of diabetic peripheral neuropathy does face some challenges and difficulties, mainly including the following:

[0004] Complex pathogenesis: The pathogenesis of DPI involves multiple mechanisms such as polyol pathway activation, oxidative stress, and microcirculatory disorders, which makes it difficult for a single treatment to fully solve the problem. Diverse symptoms: The symptoms of DPI include pain, numbness, paresthesia, etc. The clinical manifestations of different patients vary greatly, requiring personalized treatment plans.

[0005] Limited therapeutic drugs: Currently, the therapeutic drugs for DPI mainly include nerve nutrition drugs, antioxidant stress drugs, drugs that inhibit aldose reductase activity, etc., but these drugs can often only relieve symptoms and are difficult to cure.

[0006] Disease progression is difficult to reverse: Once DPI occurs, there is currently no drug that can reverse the progression of peripheral neuropathy.

[0007] Difficulty in self-management: DPI treatment requires long-term self-management by patients, including blood sugar control, lifestyle changes, etc., which places high demands on patient compliance. Risk of complications: DPN may cause a variety of complications, such as diabetic foot and painless myocardial infarction, and the treatment of these complications increases the complexity of treatment.

[0008] Exosomes have intercellular communication functions and multiple biological characteristics, and can intervene in the occurrence and development of diseases through multiple pathways, and have great potential in the treatment of peripheral nerve injury diseases (Yuan Yiming, et al., Effects of exosomes in the process of peripheral nerve injury, "Chinese Journal of Tissue Engineering Research", 2020, 24(31): 5079-5084. DOI: 10.3969 / j.issn.2095-4344.2093. Patent application number: 202211407752.0, invention name: A use of stem cell exosomes in the preparation of peripheral nerve mechanical injury drugs and drugs containing stem cell exosomes, providing a use of stem cell exosomes in the preparation of peripheral nerve mechanical injury drugs Application in medicine and medicine containing stem cell exosomes. The stem cells used in the present invention have the characteristics of rich sources, easy collection, strong proliferation and differentiation ability, and can be used for "cell-free" treatment. Local or / and systemic application of stem cell-derived exosomes can be selected to treat peripheral nerve injury. Application number 202211226700.3, invention name: A method for extracting exosomes derived from bone marrow mesenchymal stem cells for repairing ischemia / reperfusion nerve damage and its application, relating to a method for extracting exosomes derived from bone marrow mesenchymal stem cells for repairing ischemia / reperfusion nerve damage and its application. It is proved that exosomes derived from bone marrow mesenchymal stem cells can effectively inhibit the apoptosis of nerve cells to protect nerve cells.

[0009] Zhao Shumei, et al., Neural stem cell exosomes: a new approach to the treatment of neurological diseases, Chinese Journal of Cell Biology, DOI: 10.11844 / cjcb.2020.08.0013, published Exosomes secreted by neural stem cells (NSCs) can participate in the physiological and pathological changes of neurological diseases and play their potential neuroregulatory and repair functions. Exosomes secreted by NSCs can play a role in the treatment of neurological diseases.

[0010] Dopamine methacrylamide (DMA) is a compound that combines the biological activity of dopamine with the chemical activity of methacrylic acid. DMA can covalently crosslink with hyaluronic acid to form a hydrogel. This hydrogel is an effective carrier for stem cells in skin regeneration therapy. It can promote cell proliferation in vitro and regeneration of skin defects in vivo. The multifunctional hydrogel dressing constructed with DMA has broad-spectrum photodynamic antibacterial ability, can inhibit bacterial aggregation and produce more singlet oxygen, and has excellent biodegradability and biocompatibility, which is conducive to wound healing. The high-toughness polydopamine-polyacrylamide (PDA-PAM) hydrogel designed with DMA has excellent self-healing ability, which is very beneficial for tissue engineering and regenerative medicine applications.

[0011] Currently, there is no literature report on the complexation of dopamine methacrylate with exosomes derived from bone marrow mesenchymal stem cells (BMSCs). Summary of the invention

[0012] The technical solution of the present invention is to provide an exosome-dopamine conjugate complex. The present invention also provides a gel patch containing the complex and a preparation method and use thereof.

[0013] The present invention provides an exosome-dopamine conjugate complex, which is prepared from dopamine methacrylate and exosomes as raw materials, and the molar ratio is: dopamine methacrylate: exosome

[0014] =1:1-5; among them, exosomes are derived from bone marrow mesenchymal stem cells.

[0015] Further preferably, the molar ratio of dopamine methacrylate to exosomes is 1:1.

[0016] Wherein, the exosomes are obtained from rat bone marrow mesenchymal stem cells, and the exosomes are collected after cell culture, and the exosomes are extracted by ultracentrifugation;

[0017] The preparation method of dopamine methacrylate is as follows: dissolving sodium bicarbonate and sodium borate in deionized water; adding dopamine thereto under the protection of nitrogen and stirring to dissolve; dissolving methacrylic anhydride in tetrahydrofuran and adding it to the above reaction solution; adjusting the pH to 8 and stirring overnight to react; after the reaction is completed, adjusting the pH value of the entire reaction system to acidic by using dilute hydrochloric acid, extracting with ethyl acetate, recrystallizing with n-hexane and vacuum drying to purify to obtain dopamine methacrylate solid;

[0018] Preferably, the ultracentrifugation conditions are as follows:

[0019] a. Centrifuge the culture medium of bone marrow mesenchymal stem cells at 300×g, 2000×g, and 10000×g for 10 min, 20 min, and 30 min, respectively;

[0020] b. Centrifuge the supernatant at 100,000 × g for 90 min to separate exosomes;

[0021] c. Wash the exosomes with PBS and centrifuge at 100,000×g for 90 min. Finally, collect the exosomes and resuspend them in 50ul PBS for later use.

[0022] The present invention provides a method for preparing the exosome-dopamine conjugate complex, which comprises the following steps:

[0023] a. Weigh the raw materials of each molar ratio;

[0024] b. Stir evenly to allow dopamine methacrylate to fully react with the thiol groups on the surface of exosomes.

[0025] The invention provides a gel patch, which contains the exosome-dopamine conjugate complex.

[0026] It is prepared from exosome-dopamine conjugate complex, aldehyde / phenylboronic acid bifunctionalized dextran, and methacrylated gelatin as raw materials, and the weight ratio is:

[0027] 1 part of exosome-dopamine conjugate complex, 20 parts of aldehyde / phenylboronic acid bifunctionalized dextran, and 20-60 parts of methacrylated gelatin;

[0028] Preferably, the weight ratio is:

[0029] 1 part of exosome-dopamine conjugate complex, 20 parts of aldehyde / phenylboronic acid bifunctionalized dextran, and 60 parts of methacrylated gelatin.

[0030] Wherein, the preparation method of the aldehyde / phenylboronic acid bifunctionalized dextran is:

[0031] a. Preparation of oxidized dextran: dissolving dextran in deionized water and sodium periodate in deionized water respectively; mixing the two solutions and stirring at room temperature; adding ethylene glycol to the mixed solution, stirring the reaction to terminate the reaction, dialyzing the reaction solution, and freeze-drying to obtain oxidized dextran;

[0032] b. Dissolve oxidized dextran and 3-aminophenylboronic acid in PBS solution respectively, then add them into a flask in sequence, and stir to react at room temperature; obtain the reaction solution and dialyze it, and then freeze-dry to obtain aldehyde / phenylboronic acid bifunctionalized dextran;

[0033] The preparation method of the methacrylated gelatin is as follows:

[0034] Gelatin was added into PBS (200 ml, pH = 7.4) solution and dissolved by stirring at 70°C; after complete dissolution, methacrylic anhydride was slowly added dropwise thereto; after stirring and reacting at 50°C for 2 hours, PBS solution was added thereto for dilution; finally, dialyzed at 50°C for 72 hours, and methacrylic gelatin (GM) was obtained after freeze-drying.

[0035] The present invention provides a method for preparing the gel patch, which comprises the following steps:

[0036] a. Add I2959 to phosphate buffered saline (PBS) to prepare a solution containing 1% I2959; then dissolve methacrylated gelatin in the I2959 solution;

[0037] b. Aldehyde / phenylboronic acid bifunctionalized dextran was dissolved in phosphate buffered saline (PBS);

[0038] c. Mix equal volumes of EXO-DMA and aldehyde / phenylboronic acid bifunctionalized dextran solution and mix them evenly; mix the mixed solution with methacrylated gelatin solution in a volume ratio of 1:1, incubate at 37°C for 20 minutes, and then inject into a mold to form a hydrogel through photocrosslinking; remove the mold to obtain a gel patch.

[0039] The present invention also provides the use of the gel patch in preparing external medicines or subcutaneous implant medicines with neuroprotective effects.

[0040] The drug is used to treat diabetic peripheral neuropathy, impaired axonal regeneration, slowed nerve conduction velocity, diabetic nerve morphological changes, and diabetic autonomic nerve dysfunction.

[0041] The beneficial effects of the present invention are:

[0042] (1) Exosomes derived from rat bone marrow mesenchymal stem cells were extracted by ultracentrifugation, and dopamine-conjugated modified exosomes (EXO-DMA) with mitochondrial targeting were constructed based on the Michael addition reaction between the thiol groups on the surface of exosomes and dopamine methacrylate.

[0043] (2) Boronic acid / aldehyde bifunctionalized dextran (ODB) and methacrylamide gelatin (GM) were synthesized, and bioactive biomimetic hydrogels were prepared by crosslinking them with dynamic imine bonds and boron ester bonds. Based on the dual dynamic network, especially the dynamic boron ester bond, the gel system was endowed with flexible mechanics, self-healing, self-adhesion, ROS scavenging and other performance foundations. Furthermore, through the dynamic covalent bonding of boronate esters between the bioactive gel and EXO-DMA, an exosome-conjugated loaded gel patch with targeted regulation of pathological microenvironment remodeling and mitochondrial dysfunction was prepared.

[0044] (3) An animal model of peripheral nerve injury in diabetic rats was established. The gel patch was self-adhesive around the injured nerve to form a tubular structure, and the neuroprotective and neurotherapeutic effects of the gel patch on diabetic PNI were investigated. The results showed that based on the targeted regulation of microenvironment remodeling and mitochondrial dysfunction, the exosome-conjugated loaded gel patch could effectively promote axon regeneration, myelination and motor function recovery in diabetic PNI rats.

[0045] The present invention uses exosomes derived from bone marrow mesenchymal stem cells in combination with dopamine methacrylate in the form of a conjugated complex to exert a synergistic effect. The prepared gel patch can effectively promote diabetic axon regeneration, myelination and motor function recovery. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 Extraction and related characterization of exosomes ((A) Extraction process of exosomes (B) TEM image (C) Particle size distribution diagram (D) Analysis of characteristic proteins on the surface of exosomes by WB test (CD9, CD63, AND TSG101));

[0047] Figure 2 Synthetic route of DMA and 1 H NMR spectrum;

[0048] Figure 3 (A) Schematic diagram of the synthesis of EXO-DMA. (B) UV absorption spectra of EXO, DMA, and EXO-DMA. (C) Changes in the thiol content of EXO and EXO-DMA. (D) Zeta potential diagram of EXO and EXO-DMA;

[0049] Figure 4 Confocal fluorescence images of PKH26-labeled EXO-DMA (green) or EXO (green) and rhodamine 123-labeled mitochondria (red) and colocalization trend curve analysis. R is the Pearson correlation coefficient between red fluorescence and green fluorescence;

[0050] Figure 5 Subcellular localization of PKH26-labeled EXO-DMA (green) in the nucleus, endoplasmic reticulum, lysosomes, and Golgi apparatus. R is the Pearson correlation coefficient between red fluorescence and green or blue fluorescence;

[0051] Figure 6 (A) Schematic diagram of the synthesis of Dex-CHO-BA (ODB). (B) FT-IR spectrum of ODB. (C) 1 H NMR spectroscopy;

[0052] Figure 7 (A) Schematic diagram of the synthesis of Gel-MA (GM). (B) FT-IR spectrum of GM. (C) 1 H NMR spectroscopy;

[0053] Figure 8 FT-IR spectrum;

[0054] Fig. 9 (A) Angular frequency sweep test (B) Continuous step strain test (C) Tensile test (D) Schematic diagram of curling and wrapping;

[0055] Fig.10 (A) Schematic diagram of GM-ODB / ED hydrogel adhesion on pigs. (B) Adhesion strength test and peeling test;

[0056] Fig.11ROS scavenging and reactive release in pathological microenvironment. (A) DPPH scavenging. (B) Cumulative release of dopamine-exosome conjugates.

[0057] Fig.12 Flow cytometric analysis of apoptosis of RSC96 cells under different culture conditions;

[0058] Fig.13 (A) Confocal laser scanning microscopy images and 3D surface images of DCFH-DA staining (green, DCFH-DA; blue, cell nucleus). (B) Mitochondrial morphology and skeleton analysis by rhodamine 123 staining. Left: Fluorescence image. Middle: Mitochondrial threshold and skeleton image processed by ImageJ. Right: Enlarged image of mitochondrial skeleton. (C) Representative fluorescence images and 3D surface images of JC-1 staining;

[0059] Fig.14 Typical fluorescence images of mitochondria stained with rhodamine 123 after RSC96 cells were treated with high glucose for 24 h;

[0060] Fig.15 (A) Fluorescence images of DCFH-DA staining after 1 and 3 days of culture. (B) Statistical analysis of DCFH-DA in RSC96 cells;

[0061] Fig.16 (A) Fluorescence images of JC-1 staining of RSC96 cells injured by hyperglycemia after 1 and 3 days of culture; (B) Statistical analysis of the aggregate / monomer ratio of RSC96 cells;

[0062] Fig.17 (A) Representative immunofluorescence staining of RSC96 cells after 3 days of culture (E-cadherin, green; F-actin, red; nuclei, blue; AMPK, green); (B) Quantitative statistics of E-cadherin and AMPK expression;

[0063] Fig.18 ATP production in damaged RSC96 cells after 3 days of culture;

[0064] Fig.19 Changes in blood glucose and body weight of mice injected with different concentrations of STZ within 28 days;

[0065] Fig. 20 Schematic diagram and surgical procedure of GM-ODB / ED gel patch implanted into the sciatic nerve of diabetic rats;

[0066] Fig.21 Schematic diagram of the modeling and repair process of diabetic PNI;

[0067] Fig. 22Representative immunofluorescence images and quantitative statistics of SOD and TNF-α expression in the sciatic nerve 1 week after hydrogel patch implantation;

[0068] Fig.23 TEM images of sciatic nerve cross sections and mitochondrial characterization (red arrows, damaged mitochondria; yellow arrows, healthy mitochondria);

[0069] Fig.24 (AB) Representative immunofluorescence images and quantitative statistics of BAX, BCL2 and CYTC; (C) Mechanistic illustration of GM-ODB / ED promoting mitochondrial protection through pathological microenvironment correction;

[0070] Fig.25 H&E staining of sciatic nerve during treatment and 4 weeks after treatment;

[0071] Fig.26 Representative immunofluorescence images and quantitative statistics of NF200, MBP, and S100 expression;

[0072] Fig. 27 (AB) Gait analysis and SFI calculation of diabetic PNI rats; (C) CMAP recording and onset peak amplitude. DETAILED DESCRIPTION

[0073] Example 1 Preparation of the exosome-dopamine conjugate complex EXO-DMA of the present invention

[0074] 1. Isolation of exosomes (EXO) from rat bone marrow mesenchymal stem cells (BMSCs)

[0075] In a sterile environment, bilateral humerus and femur of SD rats (n=5, 1 week old) were removed, and the metaphysis of the bones was removed. A-MEM medium (Gibco) containing 10% fetal bovine serum (Gibco) and 1% penicillin / streptomycin was prepared, and the bone marrow cavity was flushed 3-5 times until the color of the bone marrow cavity turned white. Finally, the extracted bone marrow mesenchymal stem cells (BMSCs) were cultured at 37°C and 5% CO2.

[0076] When the density of BMSCs reached 70-80%, the culture medium without fetal bovine serum was used to replace the conventional culture medium for continued culture. After 48 hours, the culture medium was collected and the exosomes derived from BMSCs were extracted by ultracentrifugation. Specific experimental steps: First, the culture medium was centrifuged at 300×g, 2000×g, and 10000×g for 10 minutes, 20 minutes, and 30 minutes, respectively, to remove dead cells and cell debris; then the supernatant was centrifuged at 100,000×g for 90 minutes to separate the exosomes; then the exosomes were washed with PBS and centrifuged at 100,000×g for 90 minutes; finally, the exosomes were collected and resuspended with 50ul PBS for later use. The particle size of the exosomes was analyzed by a particle size analyzer (Nano FCM, N30E, China). The morphology of the exosomes was observed using a transmission electron microscope (TEM, JEM-2100Plus, Japan). Western blotting experiments were used to detect the expression of exosome surface proteins CD9, CD63, and TSG101.

[0077] 2. Preparation of dopamine methacrylate (DMA)

[0078] Dissolve sodium bicarbonate (4g) and sodium borate (10g) in deionized water (100ml). Under the protection of nitrogen, add dopamine (5g) and stir to dissolve. Dissolve methacrylic anhydride (4.7ml) in 25ml of tetrahydrofuran and add to the above reaction solution. Adjust the pH to 8 and stir to react overnight. After the reaction is completed, adjust the pH value of the entire reaction system to acidic with dilute hydrochloric acid, extract with ethyl acetate, recrystallize with n-hexane and vacuum dry to obtain DMA solid. Store DMA at -20℃ for future use. Dissolve DMA in DMSO and 1 Its molecular structure was determined by H NMR analysis. DMA synthesis can also be carried out according to the method disclosed in the literature (DOI: 10.1002 / adfm.201805964).

[0079] 3. Preparation of exosome-dopamine conjugate complex (EXO-DMA)

[0080] DMA was mixed with EXO (mole ratio of thiol group: acrylate group = 1:1), stirred evenly, and oscillated at 37°C for 15 min to allow DMA to fully react with the thiol groups on the surface of exosomes. The thiol content on the surface of exosomes was analyzed by thiol fluorescent probe. The EXO-DMA suspension was dispersed and the Zeta potential was analyzed by dynamic light scattering. UV-visible absorption spectroscopy was performed using a UV-visible spectrometer (U-3900, Hitachi).

[0081] 4. Characterization of EXO-DMA targeting to mitochondria

[0082] RSC96 cells were cultured at 1×10 5 cells / mL were inoculated into glass-bottomed cell culture dishes and cultured in DMEF medium containing 10% fetal bovine serum and 1% penicillin / streptomycin. After 24 hours, PKH26-labeled EXO and EXO-DMA were added to the culture dishes respectively and cultured for another 24 hours. Rhodamine 123 was then added to the culture dishes to stain the mitochondria in the cells. Fluorescence images were obtained by observation using a Zeiss LSM 880 laser scanning confocal microscope. The overlap coefficient was calculated using ImageJ software. Different probes were used to stain the organelles, and the distribution of the PKH26-labeled EXO-DMA complex in the subcellular organelles was verified by following similar steps as above.

[0083] 5. Extraction and characterization of EXO

[0084] like Figure 1 As shown in A, exosomes derived from bone marrow mesenchymal stem cells were extracted by ultra-high speed centrifugation. Transmission electron microscopy images showed that the extract was a tray-shaped nanoparticle ( Figure 1 B), which meets the basic characteristics of exosomes; the nanoparticle size analyzer shows that the particle size is in the range of 70-150nm, which meets the particle size conditions of exosomes ( Figure 1 C). Meanwhile, the results of Western blot analysis showed that the expression of CD9, CD63, and TSG101 proteins in exosomes was higher than that in BMSCs ( Figure 1 D). Combining the above three test results, it proves that the exosome extraction is successful.

[0085] 6. Preparation and characterization of DMA

[0086] Double-bond functionalized dopamine (DMA) was prepared by amidation reaction between dopamine and methacrylic anhydride, and the successful preparation of DMA was confirmed by H-NMR spectroscopy. Figure 2 As shown, the two characteristic peaks appearing at 5.7ppm and 5.3ppm are derived from the two hydrogens on the olefin in methacrylic acid; the characteristic peaks shown at 3.4ppm and 2.6ppm are derived from the methylene peak in dopamine; the characteristic peaks appearing at 6.7ppm and 6.5ppm are derived from the phenyl proton peak in dopamine. These results prove the successful synthesis of DMA.

[0087] 7. Preparation and characterization of EXO-DMA

[0088] EXO and DMA were mixed, and EXO-DMA was prepared by Michael addition reaction between the thiol groups on the surface of exosomes and the double bonds on the DMA molecules. Figure 3A). In the UV-visible absorption spectrum curve, EXO-DMA showed a characteristic absorption peak at 280nm, which is consistent with the characteristic absorption peak of DMA, indicating that DMA was successfully modified onto the surface of EXO ( Figure 3 B). In addition, the thiol groups on the surface of exosomes were detected by thiol fluorescent probes, and the results showed that the thiol content on the surface of exosomes decreased by about 60%, which indicates that DMA is bound to the surface of exosomes by Michael addition reaction with the thiol groups on the surface of exosomes ( Figure 3 C). Zeta potential results showed that the potential of EXO modified with DMA decreased compared with that of EXO ( Figure 3 D). The above results together demonstrate the successful preparation of EXO-DMA.

[0089] 8. Test on the optimal ratio of EXO and DMA

[0090] Three groups were set up: the molar ratio of thiol groups on the surface of EXO to DMA was 1:1; 1:3; 1:5; the results showed that as the molar concentration of DMA increased, the amount of thiol groups on the surface of exosomes did not change much. That is, when the molar ratio was 1:1, the DMA modified on the exosomes had reached saturation. Therefore, the concentration of EXO to exosomes was 1:1 to prepare EXO-DMA.

[0091] 9. Analysis of mitochondrial targeting of EXO-DMA

[0092] EXO and EXO-DMA were labeled with PKH26 and mitochondria were labeled with rhodamine 123 probe to analyze the targeting ability of EXO and EXO-DMA to mitochondria. Figure 4 As shown, the confocal fluorescence images preliminarily showed that EXO-DMA had good binding with mitochondria (the green fluorescence of EXO-DMA overlapped with the red fluorescence of mitochondria to show a yellow fluorescence image). Later, the confocal fluorescence images were processed by ImageJ, and the Pearson's correlation coefficient analysis was used to prove the binding ability of EXO-DMA with mitochondria. The results showed that the Pearson's correlation coefficient between EXO-DMA and mitochondria was 0.81, which was significantly higher than the Pearson's correlation coefficient of EXO and mitochondria of 0.46. The degree of fluorescence overlap was analyzed by the co-localization trend curve, and the results showed that the fluorescence curve graph of EXO-DMA and the fluorescence curve graph of mitochondria overlapped well. The above results jointly prove the mitochondrial targeting of EXO-DMA.

[0093] The above results indicate that EXO-DMA was successfully prepared in the present invention, and its mitochondrial targeting was proved by fluorescence imaging analysis, which laid a foundation for the later mitochondrial targeted therapy.

[0094] Finally, in order to further verify the mitochondrial targeting of EXO-DMA, the present invention used different commercial dyes to stain the organelles and analyzed the distribution of EXO-DMA in the organelles. Figure 5 As shown in the figure, the confocal fluorescence images were processed by ImageJ, and the Pearson's correlation coefficients of EXO-DMA in the endoplasmic reticulum, Golgi apparatus, lysosome and nucleus were 0.59, 0.56, 0.38 and 0.19 respectively. This result shows that although EXO-DMA is also distributed in various organelles, its distribution is significantly lower than that of mitochondria.

[0095] These results collectively suggest that EXO-DMA has mitochondrial targeting based on the mitochondrial targeting provided by polyphenols.

[0096] Example 2 Preparation of the Gel Patch (GM-ODB / ED) of the Present Invention and Cell Experiment

[0097] 1. Preparation of aldehyde / phenylboronic acid bifunctionalized dextran (ODB)

[0098] Dextran (10.0g) was dissolved in 250ml of deionized water, and sodium periodate (6.34g) was dissolved in 50ml of deionized water. The two solutions were mixed and stirred at room temperature for 12h. Then, ethylene glycol (10ml) was added to the mixed solution, and the reaction was terminated after stirring for 2h. Finally, the reaction solution was dialyzed for 72h, and oxidized dextran (OD) was obtained after freeze-drying. OD (5g) and 3-aminophenylboronic acid (0.5g) were dissolved in 50ml of PBS solution, respectively, and then added to a 250ml three-necked flask in turn, and the reaction was stirred for 12h at room temperature. Finally, the reaction solution was obtained and dialyzed for 72h, and aldehyde / phenylboronic acid bifunctionalized dextran (ODB) was obtained after freeze-drying. By nuclear magnetic resonance spectroscopy 1 H NMR (AV II-600 MHz, Bruker) and infrared spectroscopy (FT-IRspectra) confirmed the grafting of aldehyde groups and boric acid on the dextran molecular chain.

[0099] 2. Preparation of methacrylated gelatin (GM)

[0100] Gelatin (20 g) was added to PBS (200 ml, pH = 7.4) solution and stirred at 70 ° C to dissolve. After complete dissolution, methacrylic anhydride (20 ml) was slowly added dropwise. After stirring at 50 ° C for 2 hours, 200 ml of PBS solution was added to dilute it. Finally, it was dialyzed at 50 ° C for 72 hours and freeze-dried to obtain methacrylic gelatin (GM). By nuclear magnetic resonance spectroscopy 1The grafting of methacrylic acid on gelatin molecular chain was characterized by H NMR (AV II-600MHz, Bruker) and FT-IR spectra.

[0101] The synthesis of aldehyde / phenylboronic acid difunctionalized dextran can be carried out according to the literature ( https: / / doi.org / 10.1016 / j.jconrel.2021.11.027 ) method; the synthesis of methacrylated gelatin can be prepared according to the method in the literature (https: / / doi.org / 10.1016 / j.carbpol.2020.116067).

[0102] 3. Preparation of gel patch

[0103] Prepare different concentrations of methacrylated gelatin (10mg / ml, 20mg / ml, 30mg / ml), take 2ml and mix with 1ml aldehyde / phenylboronic acid bifunctionalized dextran (20mg / ml) and 1ml exosome-dopamine conjugate complex (1mg / ml), inject into the mold, and form gel through photocrosslinking reaction. The results show that 30mg / ml methacrylated gelatin has the best gelling performance. Therefore, this concentration is selected for the preparation of gel patches:

[0104] 30% (w / v) GM was dissolved in phosphate buffered saline (PBS) containing 1% I2959. Secondly, 20% (w / v) ODB was dissolved in phosphate buffered saline (PBS). 1 mg of EXO-DMA was mixed with the ODB solution in equal volumes and mixed evenly. Finally, the mixed solution was mixed with the GM solution in a volume ratio of 1:1, incubated at 37°C for 20 minutes, and then injected into the mold to form a hydrogel by photocrosslinking. The mold was removed to obtain a GM-ODB / ED gel patch. According to the above preparation principle, GM-ODB and GM-ODB / E gel patches can be obtained respectively. The crosslinking of the gel network was characterized by infrared spectroscopy (FT-IR spectra).

[0105] 4. Mechanical properties analysis of GM-ODB / ED gel patch

[0106] (1) Rheological properties test

[0107] Rheological tests were performed using a rheometer (MCR-302, Anton Paar). All samples were cut into circular shapes (1.5 mm thick and 8 mm in diameter). Angular frequency sweep measurements (1-100 rads-1) were performed at a fixed strain of 1%. Strain amplitude sweep tests were performed under sweep frequency (1%-100%) conditions, and continuous step strain experiments were measured by cyclic small strain (500%) and large strain (1000%).

[0108] (2) Tensile performance test

[0109] The tensile properties of the hydrogels were measured by a dynamic mechanical analyzer (Q800, TA). The hydrogels were cut into rectangles (width: 10 mm, thickness: 1.0 mm). -1 The hydrogel is stretched at a displacement rate until it breaks.

[0110] (3) Adhesion performance test

[0111] The adhesion ability of the hydrogel was measured using the tensile mode of a dynamic mechanical analyzer (Q800, TA). First, the prepared sample and pigskin were cut into rectangles of 10 mm × 10 mm and 10 mm × 30 mm, respectively. Then, the hydrogel was sandwiched between the surfaces of two pigskins and stretched at a loading rate of 0.01 N / min. The interfacial toughness was evaluated by a 180° peel test:

[0112] Interface toughness = 2F / W

[0113] Where, F: maximum peeling force, W: hydrogel width.

[0114] (4) Response release performance test

[0115] First, prepare a PBS solution containing 1mM H2O2 and 25mM glucose in advance. Second, immerse the GM-ODB / ED gel patch in 1mL of the above solution. At a given time, take out 200μL of the supernatant for analysis and replace it with an equal amount of liquid fresh solution. Finally, use a UV-visible spectrophotometer to detect the EXO-DMA released from the hydrogel.

[0116] (5) DPPH removal performance test

[0117] The antioxidant efficiency of the hydrogels was analyzed using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging method. The same volume of hydrogel was prepared and mixed with 2 ml of ethanolic DPPH (100 μM). Then, the mixture was placed in a dark environment at 37 °C for 2 h. Subsequently, the reaction solution was analyzed using a UV-visible spectrophotometer. The calculation formula for DPPH degradation is as follows

[0118] DPPH clearance rate % = (A0-A1) / A0×100%

[0119] Wherein, A0: absorbance of blank (DPPH+ethanol); A1: absorbance of hydrogel (DPPH+ethanol+hydrogel).

[0120] 5. Screening test of matrix:

[0121] The single methacrylate gelatin (Gel-MA) is cross-linked into gel by covalent bonding, which has low toughness, is prone to breakage, and is not easy to form a gel patch. Therefore, it is necessary to introduce non-dynamic covalent bonds into methacrylate gelatin (Gel-MA) to improve toughness. To this end, the present invention achieves the preparation of a gel patch by fixing the concentration of methacrylate gelatin (Gel-MA) and introducing different concentrations of phenylboronic acid / aldehyde bifunctionalized dextran therein.

[0122] Specific experimental design: 30% (W / V) Gel-MA and 10% (W / V); 20% (W / V) ODB gel; the results showed that 30% (W / V) and 20% (W / V) ODB showed good tensile toughness, which met the preparation requirements of gel patches. Therefore, 20% (W / V) ODB concentration was selected for subsequent experimental research.

[0123] 6. Dosage screening test:

[0124] Compared with unmodified EXO, the modified EXO (EXO-DMA) binds to the gel matrix through a dynamic boronate bond, achieving effective loading and controlled release of exosomes. Therefore, the present invention determines the binding effect of EXO-DMA by the change of the boric acid content in ODB. The results are as follows:

[0125] The dosage of EXO-DMA was 0.5mg, 1mg, and 1.5mg respectively; the results showed that when the concentration was 1mg, the amount of boric acid was significantly reduced, indicating that EXO-DMA was effectively loaded in the gel. Therefore, 1mg was selected for subsequent experiments.

[0126] The beneficial effects of the present invention are demonstrated by pharmacodynamic tests as follows.

[0127] Experimental Example 1: "Protection and Treatment" of Cells by GM-ODB / ED Gel Patch

[0128] 1. Gel patch and cell co-culture

[0129] RSC96 cells were co-cultured with the gel patch, and RSC96 cells cultured under normal conditions (DMEM medium containing 10% FBS and 1% penicillin and streptomycin) were used as cell models for in vitro neuroprotection studies. A high-glucose-damaged RSC96 cell model was established for in vitro neurotherapy studies.

[0130] Specifically, when the cells in the culture dish are 70%-80% confluent, 50mM glucose is added to the culture medium to create a high-sugar environment. After the cells are continuously exposed to the high-sugar environment for 24 hours, the mitochondria are stained with Rhodamine 123, and the mitochondrial morphological changes are analyzed based on the staining results to assess the cell damage.

[0131] 2. Flow cytometry apoptosis analysis

[0132] RSC96 cells were co-cultured with the hydrogel patch and stimulated with H2O2 (50 μM, 1 h) to induce oxidative stress. The cells were collected and stained with the Annexin V apoptosis detection kit, and the staining was detected by flow cytometry and the cell apoptosis was analyzed.

[0133] 3. Mitochondrial morphology observation

[0134] Cells were stained with rhodamine 123 to observe mitochondrial morphology. Rhodamine 123 was added to RSC96 cells and incubated at 37°C for 30 min, and then the cells were washed three times with phosphate buffered saline (PBS). Confocal images were acquired using a Zeiss LSM 880 laser scanning confocal microscope, and the images were analyzed for mitochondrial morphology using ImageJ software.

[0135] 4. Active oxygen analysis

[0136] RSC96 cells were co-cultured with the hydrogel patch and then stimulated with H2O2 (50 μM, 1 h) to induce oxidative stress. The intracellular ROS level was assessed by DCFH-DA (10 μM, 20 min, Sigma Aldrich) staining. Cell staining images were obtained by laser scanning confocal microscopy (Zeiss LSM 880).

[0137] 5. Mitochondrial membrane potential (MMP) analysis

[0138] The cells were stained for MMP analysis using the JC-1 kit (Beyotime, Shanghai, China), and images were acquired using a Zeiss LSM 880 laser scanning confocal microscope.

[0139] 6. ATP detection

[0140] RSC96 cells injured by high glucose were co-cultured with the hydrogel patch. After 3 days of culture, the cells were collected and the ATP produced was detected using an ATP detection kit (Biyuntian, Shanghai, China).

[0141] 7. Immunofluorescence staining

[0142] After the damaged RSC96 cells were co-cultured with the hydrogel patch for 3 days, the expression of E-cadherin and AMPK was evaluated by immunofluorescence staining. The cells were first fixed with 4% (w / v) paraformaldehyde, and the membrane was broken with 0.1% triton-x solution, and finally blocked with 10% fetal bovine serum. The cells were incubated with the target primary antibody (anti-AMPK, anti-E-cadherin) at 4°C overnight. Then the corresponding secondary antibody was used, and the cells were incubated at room temperature for 1h, and finally stained with DAPI for 10min. Immunofluorescence staining was quantitatively analyzed using ImageJ software.

[0143] 8. Statistical analysis

[0144] Significance analysis was performed by one-way ANOVA or t-test in Spass software or GraphPad Prism 9 software. Statistical significance was defined as: *p<0.05, **p<0.01, ***p<0.001.

[0145] 9. Preparation and characterization of ODB

[0146] Oxidized dextran (OD) is obtained by sodium periodate oxidation reaction, and OD undergoes amidation reaction with 3-aminophenylboronic acid to obtain ODB. The reaction scheme is shown in the following figure. Figure 6 As shown. The infrared spectrum (FT-IR spectra) results show that ODB is at 1730cm -1 1340cm -1 The characteristic peaks of aldehyde and boric acid appear at 1575 cm -1 The characteristic peak of imine bond appears at , indicating that ODB has successfully grafted boric acid through amidation reaction. 1 H NMR showed that ODB had a characteristic peak of aldehyde group at 5-6 ppm and a characteristic peak of phenyl group at 7-8 ppm. These results showed that ODB was successfully prepared.

[0147] 10. Preparation and characterization of GM

[0148] GM was obtained by amidation reaction of gelatin and methacrylic anhydride. The reaction scheme is shown in the following figure. Figure 7 As shown. Infrared spectrum (FT-IR spectra) shows that, compared with the infrared spectrum curve of gelatin (Gel), GM has a -1 950cm -1 and 880cm -1 The characteristic peak of double bond (MA) appeared, which indicated that the double bond group was successfully introduced into the gelatin polymer chain. 1H NMR results showed that GM had a double bond characteristic peak at 5-6 ppm, which further proved that the double bond group was successfully introduced into the polymer chain. 1 The H NMR results collectively demonstrate the successful preparation of GM.

[0149] 11. Preparation and characterization of GM-ODB / ED

[0150] EXO-DMA, ODB and GM were uniformly mixed, and the GM-ODB / ED gel patch was finally obtained through imine bond formation reaction, borate ester reaction and photocrosslinking reaction. The valence bond reaction involved in the gel network formation process was analyzed by infrared spectroscopy (FT-IR spectra). Figure 8 As shown, at 1533cm -1 The absorption peak at 1450cm-1 may be due to the formation of imine bonds in the gel network. In addition, due to the formation of borate ester network, -1 The characteristic peaks of borate esters were also observed.

[0151] 12. Flexibility Mechanics of Gel Patches

[0152] 12.1 Rheological properties

[0153] Matrix mechanics is a key factor affecting cell survival. Theoretically, the gel network contains abundant dynamic imine bonds and borate bonds, which can enable the gel patch to provide basic support and protection for cell survival. Fig. 9 As shown in A, the rheological test results show that GM-ODB / ED exhibits a stable average G' of ~163 Pa. It meets the mechanical adaptation requirements of neural tissue (100-1000 Pa), which provides ideal mechanical support for neuroprotection and axon extension. Fig. 9 The continuous step strain analysis in B shows that the hydrogel network has autonomous and efficient self-healing ability under shear strain with alternating amplitudes of 500% and 1000%. The tensile test shows that the tensile strength and maximum tensile strain of GM-ODB / ED hydrogel are ∼42 kPa and 23% ( Fig. 9 C). The flexibility of the hydrogel ensures that the patch makes conformal contact with the curved nerve surface, thereby adapting to the curved nerve surface. Subsequent curling and wrapping experiments further confirmed this. The hydrogel patch can be easily and continuously wrapped, folded, and bent without breaking ( Fig. 9 D).

[0154] 12.2 Adhesion properties

[0155] like Fig.10As shown in Figure A, the hydrogel patch can be tightly and seamlessly adhered to the inner surface of pig skin. After undergoing various deformation actions (including common stretching, bending and twisting), it still maintains close contact with the tissue interface and does not show obvious shedding even when washed with water. The adhesion strength of the gel patch was then quantitatively evaluated. Fig.10 As shown in Figure B, the adhesion ability of the hydrogel samples to pig skin, glass, metal, and plastic substrates was evaluated by lap shear tests. The results showed that with the addition of EXO-DMA, the adhesion ability of the hydrogel gradually increased and reached a peak in GM-ODB / ED. Similarly, the peel test on the tissue surface also confirmed that GM-ODB / ED had a 10±0.6 J / M 2 The above results show that the hydrogel has tissue adhesion and flexible curling properties, can automatically adhere to the damaged nerve, and can bend into a tubular structure of matching size.

[0156] 12.3 ROS Scavenging and Response Release

[0157] The ROS scavenging ability of GM-ODB / ED hydrogel was evaluated in vitro using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay. Fig.11 As shown in A, the clearance efficiency of GM-ODB / ED (about 80%) was significantly higher than that of the other two groups (about 20%). This phenomenon once again reflects the synergistic effect of boronate bond and dopamine modification on neuroprotection. At the same time, EXO-DMA can also be released from the hydrogel patch in a timely manner. After 48 hours of exposure to ROS and glucose environment, the release rates of EXO-DMA were 73% and 60%, respectively, which were significantly higher than the 20% release rate in PBS ( Fig.11 B). Compared with healthy physiological conditions, EXO-DMA can be released spontaneously and controllably under the regulation of the pathological microenvironmental cues of diabetic PNI, which greatly improves the therapeutic effect of EXO-DMA.

[0158] 13. Protective effect of gel patch on nerve cells

[0159] 13.1 Gel patch provides neuroprotection and reduces cell apoptosis

[0160] RSC96 cells were co-cultured with the gel patch, and 50 μM H2O2 was added to the culture medium to create an oxidative stress microenvironment. Flow cytometry was used to characterize cell apoptosis. Fig.12As shown in the figure, under the condition of H2O2 alone, the apoptosis rate of cells reached 40.96%. When the cells were co-cultured with GM-ODB / ED, a significant recovery of cell viability was observed, which was reduced to 14.85%. However, the protective effect of GM-ODB was slightly weaker, and the apoptosis rate of cells only recovered to 25.2%. This result shows that dopamine-modified exosomes are beneficial for cell protection.

[0161] 13.2 Study on the protective mechanism of gel patch

[0162] In order to investigate the potential neuroprotective mechanism of GM-ODB / ED, the ROS level in H2O2-stimulated RSC96 cells was identified by using the ROS indicator 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA). Under normal circumstances, DCFH-DA is cleaved by intracellular esterases to become non-fluorescent DCFH. If there are a large number of ROS in the cells, DCFH is easy to combine with ROS to generate DCF with green fluorescence. Fig.13 As shown in A, exposure to H2O2 resulted in a large amount of cellular ROS production in RSC96 cells, while the green fluorescence DCFH observed in cells co-cultured with hydrogels was significantly weaker. In contrast, cells cultured with GM-ODB / ED showed the lowest green fluorescence intensity, implying its excellent ROS scavenging ability.

[0163] To further prove this hypothesis, the present invention analyzed the mitochondrial morphology and mitochondrial membrane potential (MMP). First, the mitochondria were stained with Rodamin123, and the mitochondrial images were obtained by confocal microscopy. Finally, the mitochondrial skeleton was analyzed using ImageJ software. Fig.13 As shown in B, in RSC96 cells stimulated by H2O2, the number of mitochondria decreased significantly, and their morphology was mainly dot-like or rod-like structures. In cells co-cultured with GM-ODB / ED, the number of mitochondria increased significantly and returned to the same long strip or mesh-like morphology as the control group. JC-1 was then used to detect the changes in MMP of cells in different culture methods. As a marker of early apoptosis, JC-1 usually aggregates in the cytoplasm in a monomeric form and emits green fluorescence at low MMP values. For healthy cells, JC-1 aggregates in the mitochondrial matrix and forms red fluorescence at high MMP values. Fig.13In C, the ratio of JC-1 monomers / aggregates in RSC96 cells stimulated by H2O2 increased significantly, indicating that mitochondrial depolarization occurred during ROS-induced oxidative damage, while GM-ODB / ED culture blocked this process. In summary, these results indicate that GM-ODB / ED can inhibit apoptosis and exert neuroprotective effects by scavenging ROS in the microenvironment, reducing the occurrence of cellular oxidative stress, and maintaining the balance of cellular mitochondrial morphology and function. It is worth noting that these indicators performed best in GM-ODB / ED, which means that the neuroprotective effect was significantly improved after conjugation and loading of EXO-DMA in the hydrogel patch.

[0164] 14. The therapeutic effect of gel patch on nerve cells

[0165] 14.1 Gel patch delivers cell therapy to reduce mitochondrial dysfunction

[0166] In order to simulate the mitochondrial dysfunction of damaged neurons in diabetic PNI, the present invention pre-stimulated RSC96 cells with 50mM glucose for 24h. Fig.14 As shown, high glucose significantly disrupted the morphology of mitochondria, making them non-filamentous and weakly connected, indicating impaired mitochondrial function. Next, the reversal of damage was evaluated by co-culturing RSC96 cells damaged by high glucose with hydrogel patches. During the culture process, culture medium with 50mM glucose (high glucose) was added to simulate a continuous diabetic microenvironment, while culture medium containing 5.6mM glucose was used to simulate a normal microenvironment as a control. As a negative control, high glucose-damaged RSC96 cells that were not co-cultured with hydrogels were continuously exposed to a high glucose environment (named Glucose).

[0167] After 1 day and 3 days of cell culture, DCFH-DA staining was performed to characterize the intracellular ROS level. Fig.15 As shown in A, on the first day, more green fluorescence was observed in the glucose group while the green fluorescence in the GM-ODB / ED group was lower; on the third day, large areas of green fluorescence appeared in the glucose group, while the green fluorescence in the GM-ODB / ED group was almost unobservable. The quantitative analysis results showed that as time went on, the cells in the glucose group showed an increase in ROS, while after co-culture with the gel, the level of ROS in the cells hardly increased. Among them, the ROS level was the lowest in the GM-ODB / ED group. This result shows that the GM-ODB / ED gel patch can reduce the damage of glucose to cells and reduce the production of ROS in cells ( Fig.15B). Notably, ROS generation was also reduced in the GM-ODB group, which may be due to the scavenging of ROS by the boronate bonds in the hydrogel. However, due to the lack of targeted therapy against mitochondria, GM-ODB hydrogel can only delay but not reverse further apoptosis of cells with mitochondrial dysfunction.

[0168] Next, in order to further verify the recovery of mitochondrial dysfunction by the gel patch, the changes in mitochondrial membrane potential in cells were further characterized. Fig.16 As shown in A, in the GM-ODB / ED group, red fluorescence similar to that in the Control group can be observed, while in the Glucose group and the GM-ODB group, the red fluorescence is relatively weak. The quantitative analysis results show that the ratio of JC-1 aggregates / monomers in the GM-ODB / ED group increased significantly with the increase of time ( Fig.16 B) This result shows that GM-ODB / ED can reduce the damage of glucose to mitochondrial function and is beneficial to cell therapy.

[0169] 14.2 Study on the mechanism of promoting cell therapy by gel patch

[0170] Studies have shown that when cell activity increases, the interaction between cells will be strengthened, which will lead to an increase in E-cadherin expression, followed by the expression of AMPK, and ultimately the production of cellular energy ATP. Mitochondria are the energy source of cells, and the recovery of mitochondrial function is closely related to cell activity. Based on this, the recovery of mitochondrial function will be conducive to the increase of cell activity, thereby promoting the production of E-cadherin, AMPK and ATP in the later stage. This hypothesis was then verified through experiments. Fig.17 As shown in A, the expression of E-cadherin and AMPK in cells was analyzed by immunofluorescence staining. The results showed that after GM-ODB / ED was co-cultured with cells, the fluorescence signals of both E-Cadherin and AMPK were relatively strong. Quantitative analysis of fluorescence intensity also showed that the expression of these two proteins was the highest in the GM-ODB / ED group ( Fig.17 B) EXO-DMA promoted the recovery of cell activity due to its targeted therapeutic effect on mitochondria.

[0171] In addition, the production of intracellular ATP was also examined to characterize the reversal effect of mitochondrial function. Generally speaking, elevated ROS levels inactivate key enzymes in mitochondrial metabolism, thereby reducing ATP production. Fig.18As shown, after 3 days of incubation with GM-ODB / ED, the ATP concentration in high-glucose damaged RSC96 cells increased significantly (3.71±0.24), even close to the control group (5.27±1.02). In contrast, the ATP concentrations in the GM-ODB group and the glucose group were significantly lower (0.54±0.21 and 0.29±0.12, respectively), with no statistically significant difference. This is consistent with the results of JC-1, indicating that GM-ODB / ED can help damaged cells restore bioenergy synthesis and reverse mitochondrial dysfunction.

[0172] Experimental Example 2 Animal Experiment of the Gel of the Present Invention

[0173] 1. Experimental Animals

[0174] Female Sprague-Dawley (SD) rats (200-220 g) were purchased from Chengdu Dashuo Experimental Animal Company. All animal experiments were approved by the Medical Ethics Committee of Sichuan University (KS2022864). After the rats were purchased, they were fed normally for one week before surgery.

[0175] 2. Construction of diabetic PNI rat model and implantation of gel

[0176] Use streptozotocin (STZ) buffer to establish a diabetes model. Prepare STZ injection solution and inject STZ into rats every other day for 3 consecutive days, and continuously test the blood glucose concentration of rats. After two weeks, select rats with stable blood glucose concentration above 15.6mmol / L for subsequent experiments.

[0177] The diabetic sciatic nerve crush injury model was established. First, rats were intraperitoneally injected with sodium pentobarbital (50 mg kg -1 ) was anesthetized and the left thigh hair was shaved. Then a 15 mm incision was made on the thigh with a scalpel, and the sciatic nerve was observed by dissecting the gluteal muscle. Then, the sciatic nerve was clamped with a vascular clamp (5 mm) for 5 minutes to create a crush injury model. Finally, the gel was implanted into the sciatic nerve injury site, and the skin was sutured.

[0178] 3. Characterization of animal tissue sections

[0179] (1) H&E staining and immunofluorescence staining of tissue sections

[0180] Seven days after surgery, sciatic nerve tissues were collected and then fixed with 4% paraformaldehyde and embedded in paraffin. Finally, neural tissue sections were immunofluorescently stained with the following primary antibodies to observe the remodeling of the microenvironment: TNF-α, SOD, BAX, BCL2, and CytC. Twenty-eight days after surgery, sciatic nerve tissues were collected and

[0181] The above methods were used for treatment. Hematoxylin and eosin (H&E) staining was used to observe nerve morphology. Immunofluorescence staining of tissue sections was performed with S100, NF200 and MBP to observe nerve regeneration.

[0182] 4. Statistical analysis

[0183] Significance analysis was performed by one-way ANOVA or t-test in Spass software or GraphPad Prism 9 software. Statistical significance was defined as: *p<0.05, **p<0.01, ***p<0.001.

[0184] 5. Animal Experiments

[0185] 5.1 Establishment of diabetic PNI rat model

[0186] First, STZ was injected to establish a diabetic rat model. Rats were treated with PBS and different concentrations of STZ (20 mg / kg, 50 mg / kg), and the changes in blood glucose concentration and body weight of the rats on the 1st, 7th, 14th, and 28th days were analyzed to determine whether the modeling was successful. Fig.19 As shown, in the PBS group, the body weight of rats has been showing an upward trend, while the blood glucose concentration did not fluctuate much and remained at a normal level. In the group with an STZ injection concentration of 20kg / mg, the body weight of rats showed a downward trend in the first 14 days, while the blood glucose concentration showed an upward trend. However, on the 28th day, the body weight of rats increased, while blood glucose decreased, showing an unstable state. In comparison, the body weight of rats injected with STZ at a concentration of 50kg / mg has been showing a downward trend, while blood glucose concentration has been showing an upward trend, showing a stable state. Therefore, rats injected with STZ at a drug concentration of 50kg / mg and with blood glucose concentrations higher than 15.6mmol / L were selected for subsequent experiments.

[0187] Next, a sciatic nerve crush injury model was established in the left leg of diabetic rats. Fig. 20 As shown, the nerve after compression injury appears translucent compared to the normal sciatic nerve. The experiment was randomly divided into four groups, including sham operation group, PNI group, GM-ODB group and GM-ODB / ED group. In the GM-ODB group and GM-ODB / ED group, the patch was implanted by curling bandage without any other suture. In the PNI group, the sciatic nerve was only compressed without any material implanted. In the prosthesis group (Sham), the thigh was dissected and the sciatic nerve was exposed. No other treatment was done and it was sutured directly. Nerve tissue was collected for analysis 7 and 28 days after surgery.

[0188] 5.2 Gel patch promotes matrix microenvironment remodeling and protects mitochondrial function

[0189] In previous in vitro experiments, GM-ODB / ED has been shown to have mitochondrial-related cytoprotective and therapeutic functions. To study its in vivo application, GM-ODB / ED hydrogels were implanted into the injury site to further study the repair of diabetic PNI rats ( Fig.21 ).

[0190] Seven days after surgery, oxidative damage in the injured area was assessed by superoxide dismutase (SOD) fluorescence staining. Superoxide dismutase (SOD) is an antioxidant reductase that plays an important role in maintaining the balance of the intracellular microenvironment and can convert superoxide anions into oxygen and hydrogen peroxide. Fig. 22 As shown in A, the highest fluorescence intensity was detected in the GM-ODB / ED group, indicating that the conjugate loading of EXO-DMA is beneficial to upregulate antioxidant enzymes during diabetic PNI, thereby being more conducive to clearing excess ROS in the diabetic pathological microenvironment and promoting the recovery of the pathological microenvironment. Next, the inflammation in the microenvironment was evaluated by tumor necrosis factor-α (TNF-α) fluorescence staining. In the presence of GM-ODB / ED, the intracellular fluorescence of TNF-α was significantly quenched, indicating that GM-ODB / ED can reduce the occurrence of inflammation in the microenvironment. Based on the staining images, the expression of SOD and TNF-α was quantitatively analyzed. Fig. 22 As shown in B, in the GM-ODB / ED group, the expressions of SOD and TNF-α were similar to those in the Sham group.

[0191] These results indicate that the presence of EXO-DMA in GM-ODB / ED can reduce the ROS produced in the lesion site, promote the transformation of the pathological microenvironment to a regenerative microenvironment, and provide favorable conditions for the repair of diabetic PNI in the later stages.

[0192] Seven days after surgery, the morphology of mitochondria was observed by TEM to evaluate the protective effect of GM-ODB / ED on mitochondria after surgery. The morphology of mitochondria is closely related to mitochondrial dysfunction. When mitochondria are dysfunctional, their morphology will change accordingly, presenting a pathological state different from the normal state. Fig.23 As shown in the figure, in the PNI group, the mitochondrial morphology was mostly vacuolar vesicles, indicating that the mitochondria were damaged. In contrast, the mitochondria in the GM-ODB / ED group showed the most uniform and dense morphology, which was similar to the normal mitochondrial structure, proving that GM-ODB / ED has a protective effect on mitochondria. In addition to directly observing the morphological changes of mitochondria, the mitochondrial-related expression proteins pro-apoptotic protein (BAX) and anti-apoptotic protein (BCL2) were used to further evaluate the protective efficacy of GM-ODB / ED on mitochondria. Fig.24As shown in A&B, the immunofluorescence image results and quantitative analysis results showed that GM-ODB / ED had the strongest regulatory effects on upregulating BCL2 and downregulating BAX expression compared with other groups, and they ultimately led to the lowest reduction of CytC.

[0193] In summary, GM-ODB / ED not only corrects diabetic pathology and reshapes the cellular microenvironment, but also delivers mitochondrial-targeted therapeutic factors in a microenvironmental cue-responsive manner. This two-pronged strategy provides protective regenerative support for damaged neural tissue, including anti-inflammation, mitochondrial protection, and inhibition of apoptosis ( Fig.24 C).

[0194] 5.3 Hydrogel patch promotes nerve regeneration and motor function recovery in diabetic PNI rats

[0195] Four weeks after surgery, HE staining was used to demonstrate the promoting effect of GM-ODB / ED gel patch on nerve regeneration. Fig.25 As shown in the figure, H&E staining results showed that the axonal fibers in the PNI group were sparse and hollow, with obvious damage, while the axonal fibers in the GM-ODB / ED group were highly concentrated and neatly arranged, with a structure similar to that of the Sham group. In contrast, the repair effect of nerve fibers in the GM-ODB group was between the above two groups.

[0196] The expression of neurofilament 200 (NF200), myelin basic protein (MBP) and S100 was detected by immunofluorescence staining to further verify the efficacy of GM-ODB / ED on diabetic peripheral nerve injury in rats. NF200 is a neurofilament-specific marker for predicting axon regeneration. Fig.26 As shown, the sciatic nerve fibers of rats in the GM-ODB / ED group were linearly distributed and the regenerated structures were well oriented. In addition, the expression of structural proteins representing axons (NF200) and myelin (MBP and S100) in the GM-ODB / ED group was significantly upregulated compared with the PNI and GM-ODB groups. These observations suggest that GM-ODB / ED hydrogel treatment can significantly improve axonal elongation and remyelination of nerve fibers in diabetic PNI.

[0197] In the above experiments, HE staining and immunofluorescence staining were used to demonstrate the regenerative effect of GM-ODB / ED gel patch on diabetic PNI from the histological level. Diabetic PNI usually causes impaired motor function in patients. Therefore, functional recovery after injury is an important indicator for evaluating the repair of diabetic PNI injury. The recovery of motor function and nerve impulse conduction in diabetic PNI rats was verified by footprint test and electrophysiological analysis. First, the recovery of motor function was evaluated by gait analysis system, and the sciatic nerve function index (SFI) was calculated to reflect the degree of sciatic nerve dysfunction. Fig. 27 The gait images in A show that the footprints of the GM-ODB / ED group in the Sham group were relatively short compared with those of the GM-OD group. The footprints of the PNI group were the longest. The SFI statistics also showed that the recovery rate of the GM-ODB / ED group was significantly higher (SFI = -44.13 ± 11.67, Fig. 27 B) In addition, electrophysiological analysis was performed to assess the reinnervation of the gastrocnemius muscle distal to the injured nerve. Fig. 27 As shown in C, the peak value of electrophysiological recording of complex muscle action potential (CMAP) in the GM-ODB / ED group was significantly higher than that in the GM-ODB group and the PNI group, indicating that the nerve fibers were denser and the motor performance was better. These results confirmed that GM-ODB / ED can promote nerve regeneration and promote the treatment of diabetic PNI rats.

Claims

1. An exosome-dopamine conjugate complex, characterized in that: It is prepared from dopamine methacrylate and exosomes as raw materials, and the molar ratio thereof is: dopamine methacrylate: exosomes = 1:1-5; wherein, the exosomes are derived from bone marrow mesenchymal stem cells.

2. The exosome-dopamine conjugate complex according to claim 1, characterized in that: The molar ratio of dopamine methacrylate to exosomes is 1:

1.

3. The exosome-dopamine conjugate complex according to claim 1 or 2, characterized in that: The exosomes are obtained from rat bone marrow mesenchymal stem cells, which are cultured and then collected, and then extracted by ultracentrifugation. The preparation method of dopamine methacrylate is as follows: dissolving sodium bicarbonate and sodium borate in deionized water; adding dopamine thereto under the protection of nitrogen and stirring to dissolve; dissolving methacrylic anhydride in tetrahydrofuran and adding it to the above reaction solution; adjusting the pH to 8 and stirring overnight to react; after the reaction is completed, adjusting the pH value of the entire reaction system to acidic by using dilute hydrochloric acid, extracting with ethyl acetate, recrystallizing with n-hexane and vacuum drying to purify to obtain dopamine methacrylate solid; Preferably, the ultracentrifugation conditions are as follows: a. Centrifuge the culture medium of bone marrow mesenchymal stem cells at 300×g, 2000×g, and 10000×g for 10 min, 20 min, and 30 min, respectively; b. Centrifuge the supernatant at 100,000 × g for 90 min to separate exosomes; c. Wash the exosomes with PBS and centrifuge at 100,000×g for 90 min. Finally, collect the exosomes and resuspend them in 50ul PBS for later use.

4. A method for preparing the exosome-dopamine conjugate complex according to any one of claims 1 to 3, characterized in that: It includes the following steps: a. Weigh the raw materials of each molar ratio; b. Stir evenly to allow dopamine methacrylate to fully react with the thiol groups on the surface of exosomes.

5. A gel patch, characterized in that: It contains the exosome-dopamine conjugate complex described in any one of claims 1 to 3.

6. The gel patch according to claim 5, characterized in that: It is prepared from exosome-dopamine conjugate complex, aldehyde / phenylboronic acid bifunctionalized dextran, and methacrylated gelatin as raw materials, and the weight ratio is: 1 part of exosome-dopamine conjugate complex, 20 parts of aldehyde / phenylboronic acid bifunctionalized dextran, and 20-60 parts of methacrylated gelatin; Preferably, the weight ratio is: 1 part of exosome-dopamine conjugate complex, 20 parts of aldehyde / phenylboronic acid bifunctionalized dextran, and 60 parts of methacrylated gelatin.

7. The gel patch according to claim 6, characterized in that: The preparation method of the aldehyde / phenylboronic acid bifunctionalized dextran is as follows: a. Preparation of oxidized dextran: dissolving dextran in deionized water and sodium periodate in deionized water respectively; mixing the two solutions and stirring at room temperature; adding ethylene glycol to the mixed solution, stirring the reaction to terminate the reaction, dialyzing the reaction solution, and freeze-drying to obtain oxidized dextran; b. Dissolve oxidized dextran and 3-aminophenylboronic acid in PBS solution respectively, then add them into a flask in sequence, and stir to react at room temperature; obtain the reaction solution and dialyze it, and then freeze-dry to obtain aldehyde / phenylboronic acid bifunctionalized dextran; The preparation method of the methacrylated gelatin is as follows: Gelatin was added into PBS solution and stirred to dissolve at 70°C; after complete dissolution, methacrylic anhydride was slowly added thereto; after stirring and reacting at 50°C for 2 hours, PBS solution was added thereto for dilution; finally, dialyzed at 50°C for 72 hours, and methacrylic gelatin (GM) was obtained after freeze-drying.

8. The method for preparing the gel patch according to claim 6 or 7, characterized in that: It includes the following steps: a. Add I2959 to phosphate buffered saline (PBS) to prepare a solution containing 1% I2959; then dissolve methacrylated gelatin in the I2959 solution; b. Aldehyde / phenylboronic acid bifunctionalized dextran was dissolved in phosphate buffered saline (PBS); c. Mix equal volumes of EXO-DMA and aldehyde / phenylboronic acid bifunctionalized dextran solution and mix them evenly; mix the mixed solution with methacrylated gelatin solution in a volume ratio of 1:1, incubate at 37°C for 20 minutes, and then inject into a mold to form a hydrogel through photocrosslinking; remove the mold to obtain a gel patch.

9. Use of the gel patch according to any one of claims 5 to 7 in the preparation of external medicines or subcutaneous implantable drugs with neuroprotective effects.

10. The use according to claim 9, characterized in that: The medicine is a medicine for treating diabetic peripheral neuropathy, impaired axonal regeneration, slowed nerve conduction velocity, diabetic nerve morphological changes, and diabetic autonomic nerve dysfunction.

Citation Information

Cited By

  • Injectable acellular matrix as well as preparation method and application thereof

    CN122182870A